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A B S T R A C T
Aim: Tanacetum parthenium L. Schultz-Bip (Asteraceae) is widely used worldwide in traditional medicine for
the treatment of convulsions and culture-bound syndromes such as susto (fear). The aim of this work was to
evaluate the anxiolytic- and antidepressant-like eﬀects of an aqueous extract of T. parthenium in behavioral
paradigms in mice. The eﬀects of T. parthenium were compared with those produced by anxiolytic and
antidepressant drugs. We carried out the chemical characterization of the main constituents of T. parthenium.
The involvement with the GABAergic and serotoninergic neurotransmitter systems were explored be means of
synergic and antagonist experiments.
Materials and methods: The anxiolytic-like eﬀect was evaluated using the Burying Behavior Test (BBT) and the
Elevated Plus-Maze Test (PMT). The antidepressant-like eﬀect was evaluated in the Forced Swimming Test
(FST), and ambulatory activity was assessed in the Open Field Test (OFT). Employing the behavioral tests,
synergism and antagonism experiments with Alprazolam, Muscimol, and Picrotoxin were carried out in the
PMT. In a series of independent experiments, concomitant administration of T. parthenium and Alprazolam,
Fluoxetine, or p-chlorophenylalanine were conducted in the FST.
For chemical characterization, High-Performance Liquid Chromatography-Electro Spray Ionization-Mass
Spectrometry (HPLC-ESI-MS) analysis was performed.
Results: T. parthenium exerts clear anxiolytic- and antidepressant-like eﬀects in mice, without aﬀecting the
ambulatory activity of the experimental subjects.
Conclusions: Anxiolytic- and antidepressant-like T. parthenium eﬀects result, at least part from the involve-
ment of the GABAergic system. Our results support the use of Tanacetum parthenium in traditional medicine
and suggest its therapeutic potential in the comorbid anxiety and depression.
1. Introduction
Tanacetum parthenium L. Schultz-Bip (Asteraceae) is a bushy
aromatic plant with feathery leaves and daisy like ﬂowers, due
resemblance to matricaria, it is known as feverfew, is a perennial
species native to Eurasia, speciﬁcally the Balkan Peninsula, Anatolia
and the Caucasus. However, cultivation has spread it around the world,
and it is now also found in the remainder of Europe, in North America,
and in Chile (Jeﬀrey, 2001; Pareek et al., 2011). It has adapted to
Mexico, where it is known by several popular synonyms, including
altamiza (feverfew), and hierba de Santa María (St. Mary's grass),
manzanilla grande (large feverfew), manzanilla romana (Roman
chamomile), mastranzo, matlali, and yerba santa. At the State of
México; Otomí ethnia recognizes it as dhata manzanilla. The
Náhuatlacas' native culture of Tlaxcala state is also known as calteme-
sha, and it is found distributed throughout the entire country,
(Villaseñor and Espinosa, 1998). In traditional medicine in Denmark,
T. parthenium is utilized in the prophylactic treatment of migraine,
epilepsy, and convulsions, as well as a sedative and a sleep inducer
(Jäger et al., 2006, 2009).
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In Mexican traditional medicine, T. parthenium is used to relieve
ailments, such as fevers, migraine, headache, rheumatoid arthritis,
stomachache, toothache, and as an analgesic, anti-inﬂammatory, and
antispasmodic agent. This species is also employed to treat culture-
bound syndromes such as susto (roughly translated as fear), espanto
(nervousness), or quemados (burns) (Diccionario enciclopédico de la
Medicina Tradicional Mexicana, 2009; Bourbonnais-Spear et al., 2007;
Estrada-Reyes et al., 2014). Within this cross-cultural construction of
illness, there is an association between beliefs of susto and depression.
Susto has also been associated with social role stress and depressive
symptoms (Weller et al., 2008) and espanto has been related with
nervousness or nerves, to communicate anxiety and emotional distress
(Mendenhall et al., 2012). Furthermore, although its etiology is an area
of active research, American Psychiatry Association (DSMV, 2013)
associates susto with mental disorders, including a number of anxiety
and fear-related conditions (i.e., Post-Traumatic Stress Disorder
[PTSD], anxiety disorder, major depressive disorders, somatoform
disorders, and other speciﬁed neurotic disorders).
Phytochemical studies of this species have demonstrated a large
number of secondary metabolites including sesquiterpene lactones,
such as parthenolide, santamarin, and other potentially active consti-
tuents including ﬂavonols such as santin, and ﬂavonoid glycosides such
as 6-hydroxykaempferol derivatives, quercetagetin, apigenin and api-
genin 7-glucuronide, and luteolin, among others (Majdi et al., 2011;
Long et al., 2003; Chávez and Chávez, 1999; Williams et al., 1999a and
1999b).
On the other hand, in humans, there are high levels of comorbidity
between anxiety and depression disorders (Kessler et al., 2010; Kelsey
and Collimore, 2014), that share neural pathways; thus, numerous
neurotransmitters systems are involved in the underlying mechanisms
of anxiolytic and antidepressant drugs.
GABA is the principal inhibitory neurotransmitter in the mamma-
lian Central Nervous System (CNS) and plays an important role in
epilepsy and anxiety (Olsen and DeLorey, 1999; Möhler, 2006;
Treiman, 2001). Therefore, it is not surprising that modulation of
GABAergic transmission comprises one of the main mechanisms for
controlling these disorders (Morimoto et al., 2004; Sherif and Ahmed,
1995; Beleboni et al., 2004). Is widely known that anxiolytic drugs such
as the Benzodiazepines (BDZ) act to enhance the eﬀect of GABA at the
GABAA receptor, even more so, some antidepressant derivatives of
BDZ, such as Alprazolam, not only induce anxiolytic actions, but also
have antidepressant eﬀects; thus, they are useful in the treatment of
comorbid anxiety and depression.
The aim of this work was to investigate the anxiolytic- and
antidepressant-like eﬀects of an aqueous extract of T. parthenium in
behavioral paradigms in mice. The main constituents of T. parthenium
were determined by High-Performance Liquid Chromatography-
ElectroSpray Ionization-Mass Spectrometry (HPLC-ESI-MS) analysis.
The anxiolytic eﬀect of T. parthenium was evaluated utilizing the
Burying Behavior Test (BBT) and the Plus-Maze Test (PMT), and the
results compared with the eﬀects of Diazepam (DZ), and Alprazolam
(ALP). The antidepressant-like eﬀect of T. parthenium was evaluated
with the Forced Swimming Test (FST) and compared with the eﬀects of
Fluoxetine (FLX) and ALP. The eﬀects of T. parthenium on locomotor
activity were evaluated in the Open Field Test (OFT).
We also explored the possible neurotransmission pathways that
underlie T. parthenium actions using synergism with sub-eﬀective doses
of the GABAergic agonist, muscimol, with non-eﬀective doses of T.
parthenium. T. parthenium anxiolytic actions were blocked by co-
administration of T. parthenium at 5 mg/kg with Picrotoxin, a
GABAergic antagonist in the PMT. Finally, in independents experiments,
T. parthenium antidepressant eﬀects included enhancement with the co-
administration of a T. parthenium non-eﬀective dose in combination with
a non-eﬀective FLX or ALP dose in the FST, and their actions were
blocked by the combination of T. parthenium eﬀective doses with p-
chlorophenylalanine (PCPA), a serotoninergic full antagonist.
2. Materials and methods
2.1. Plant material
Leaves of Tanacetum parthenium Asteraceae (before;
Chrysanthemum parthenium) were collected in July 2014 in the
Estado de México Municipality of Zinacantepec, Contadero de
Matamoros (San José) México, in the yard of a private home
19°03′47″N 99°54′47″W altitude, 3073 m above sea level.
Botanical identiﬁcation was carried out by Óscar Hinojosa-
Espinosa, M. SC., and a sample was deposited in the Universidad
Nacional Autónoma de México (UNAM) National Herbarium (voucher
specimen number: MEXU1392990).
The aerial parts of Tanacetum parthenium were air-dried and
ﬁnely ground and aqueous extracts were prepared at a ratio of 10 g of
vegetal material per 90 mL of boiling distilled water and heated for
10 min. The resulting extract was allowed to cool to room temperature,
ﬁltered, and dried in a Heto FD3 freezer dryer at –50 °C and 0.01
mBar, yielding 15.1% (1.51 g) of dried aqueous extract. The extract was
stored −4 °C until pharmacological assays or HPLC analyses were
performed. To facilitate HPLC analysis, 20-mg aliquots of the aqueous
extract were ﬁltered through an OASIS Waters HLB 1 cc pre-column,
eluted with H2O, H2O-MeOH mixtures (80:20, 50:50, and 20:80),
MeOH, and MeCN prior to HPLC analysis.
2.1.1. Aqueous extract analysis by HPLC-ESI-MS
The aqueous extract was analyzed by Aligent Technologies 1200
Series HPLC, utilizing a Millennium Chromatography Manager (464)
system, with an Ultraviolet (UV) Detector of Diode (DAD) rearrange-
ment (Waters 2996). Reverse-phase separation was conducted at room
temperature, employing a Synergi Polar-RP 80A 150×2.00 mm I.D.,
with a 4 -µm particle size. The column was eluted at a ﬂow-rate of
0.2 mL/min, in gradient mode, with mixtures of MeOH/H2O (3:97;
5 min), MeOH/H2O (80:20; 40 min), and H2O (5 min), for a total
runtime of 50 min. Elution was monitored at 220 and 254 nm. HPLC
was coupled to a Bruker Daltonics Esquire 6000 mass spectrometer.
An aliquot of the aqueous extract was ﬁltered through C18 Waters
Sep-Pak® cartridges. Three fractions were obtained and injected into
the HPLC system. Santin [1] and santamarin [2] were previously
isolated from organic extracts of Tanacetum parthenium and served as
standards. HPLC peaks were not corrected for response factors and are
reported as relative percentage of the area (Estrada-Reyes et al., 2010).
The identity and purity of the standards were conﬁrmed by their
physical and chemical properties and their spectral data (1H and 13C
Nuclear Magnetic Resonance [NMR] and MS), by means of comparison
with results described in the literature.
2.2. Pharmacological evaluations
2.2.1. Animals
Adult male Swiss Webster mice (weighing 20–30 g) were obtained
from the Vivarium at the Instituto Nacional de Psiquiatría Ramón de la
Fuente Muñiz (INPRFM) Vivarium. All animals were housed eight per
cage in a temperature-controlled (20–21 °C) room under inverted
light:dark conditions (12 h:12 h, lights on at 22:00 h). All behavioral
evaluations were performed between 10:00 and 14:00 h. Animals had
ad libitum access to Purina rodent chow and water. The animals were
managed in agreement with The General Principles of Laboratory
Animal Care (NIH publication #85-23, revised in 1985) and the
'Norma Oﬁcial Mexicana' (NOM-062-ZOO-1999); furthermore, the
experimental protocol was approved by the local ethical committee
(NC093620.0).
2.2.2. Drugs and dosage
Doses are expressed as milligrams of drug per kilogram of Body
Weight (BW) per mouse. T. parthenium (TP) (0.5, 1.0, 5, 10, 20, and
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40 mg/kg) was dissolved in saline (0.9% NaCl) and administered orally
(p.o.) by gastric gavage. Diazepam (DZ; 0.25, 0.5, 1, or 2 mg/kg),
Muscimol (MUS; 0.5 mg/kg),
Fluoxetine (FLX; 10 mg/kg), p-chlorophenylalanine (PCPA;
100 mg/kg), Picrotoxin (PTX; 0.5 mg/kg), and Alprazolam (ALP;
0.062, 1.25, 0.25, and 0.5 mg/kg) were purchased from Sigma-
Aldrich, (Mexico City, Mexico). These were dissolved in saline and
administered Intraperitoneally (IP). Control animals received the same
volume of the vehicle (saline, 0.9% NaCl). For habituation, all mice
received a daily p.o. or IP administration of saline for 5 days prior to
treatment. Each treatment had its own control group, which was
treated with the corresponding vehicle. Drugs were administered
30 min before the test, and all experiments were performed with
independent groups of eight mice each.
2.2.2.1. Burying Behavior Test (BBT). Mice were individually tested
in a cage with exactly the same dimensions as the home cages
(15×24×11 cm), but with an electriﬁed prod (7 cm long) emerging
from one of its walls, 2 cm above the bedding material of ﬁne sawdust.
Each time the animal touched the prod, the former received an electric
shock of 0.3 mA. The source of the shock was a constant current
shocker (direct current apparatus, manufactured by Eng. Salvador
Almanza, Bioengineering Department, INPRFM). The prod remained
electriﬁed throughout the test. Immediately after the placement of the
animal in the cage, its behavior was recorded for 10 min. Once the
animal received the ﬁrst shock, it typically moved toward the prod,
recognizing it as an aversive stimulus. The animal then sprayed and
pushed a pile of bedding material ahead with rapid alternating
movements of its forepaws. The parameters registered in this anxiety
test were burying behavior latency (time, in sec, from the ﬁrst shock to
the display of the burying behavior) and cumulative burying behavior
(cumulative time, in sec, that the animals spend burying the prod). In
this test, a decrease in cumulative burying behavior is interpreted as a
reduction in anxiety (Pinel and Treit, 1978; Treit, 1985; De Boer and
Koolhaas, 2003; López-Rubalcava et al., 2006). An increase in burying
behavior latency is considered to reﬂect decreased reactivity (the
readiness of the animal to respond to a certain condition).
2.2.2.2. Elevated Plus-Maze Test (PMT). This model has been widely
validated for measuring anxiolytic-like eﬀects in rodents (Lister, 1987).
The apparatus consisted of two opposite open arms (30×8 cm),
intersected (center platform) by two closed arms of the same
dimensions, with 19-cm-high walls. The arms were connected to an
8×8 cm central square. The apparatus was elevated 55 cm above the
ﬂoor, in a dimly illuminated room. Mice were placed individually in the
center of the plus-maze, facing an open arm. During the 5-min test, the
time spent in each arm was measured. The conventional spatial-
temporal measurements comprised the number of entries (all paws
on open or closed arms and expressed as percentage of total entries),
Time spent in the Open Arms (TOA) was expressed as a percentage of
the Time spent in the Open Arms (TOA), % TOA=TOA/TCA×100 (Time
spent in Closed Arms; TCA), % Open Arm Entries (% OAE), OAE=Open
Arm Entries/[Closed Arm Entries+Open Arm Entries]×100 and time
on the Central Platform (TC)=[TOA+TBC] −300; (300 s=test time, in
such a way that TOA+TCA+TC=300 s). Percentage of time and number
of entries in the open arms are considered indices of anxiety-level
behavior (Lister, 1987; Rocha et al., 2002). Ethological behaviors, such
as time spent on the Central Platform (CP) and number of head dipping
was also registered.
2.2.2.3. Forced Swimming Test (FST). Mice were individually placed
into glass cylinders (height: 21 cm, diameter; 14.5 cm) containing
15 cm of water at 23 ± 1 °C. All animals were forced to swim for a
15-min period (pre-test), followed by a 3-min swimming session (test)
24 h later. Total immobility time was measured in sec. Immobility
behavior was scored when the mouse remained ﬂoating and treading
water just suﬃciently to keep its nose above water. After the swimming
sessions, the mice were removed from the cylinder and carefully dried,
placed in heated cages for 20 min, and then returned to their home
cages. All experimental sessions were videotaped and later scored by an
observer who was unaware of the pharmacological treatments (Porsolt
et al., 1977a, 1977b; Martínez-Vázquez et al., 2012).
2.2.2.4. Open Field Test (OFT). To discard possible unwanted or
nonspeciﬁc side eﬀects of drug treatments on locomotor activity, all
treatments studied in the anxiety and depression paradigms were
analyzed in the Open Field Test (OFT). The OFT system (LE8825,
Panlab InfraRed (IR) Harvard apparatus) consisted of Perspex panels
(45×45 cm, 2.2-cm thick) in a 2-Dimensional (2D) (X and Y axes)
square frame, a frame support, and a control unit. Each frame counted
employed 16×16 infrared beams for optimal subject detection. The
frames were controlled by independent control units. Acti Track
software was utilized to analyze the animals' trajectories. Data were
exported to a computer for analysis. The number of times the animal
entered each square (counts/10 min) was recorded. A change in counts
was considered an alteration in the locomotor activity of the
experimental subject, produced by the drugs (Estrada-Reyes et al.,
2014).
To explore the participation of the GABAergic system in the
anxiolytic- and antidepressant-like actions of T. parthenium, the
following experiments were performed.
Experiment I: PTX at 0.5 mg/kg was administered simulta-
neously with T. parthenium (5 mg/kg; −30 min) to mice, followed by
testing in the PMT.
Experiment II: One group was treated with a non-eﬀective dose
of the GABAA agonist muscimol (MUS; 0.5 mg/kg) jointly with a
threshold dose of T. parthenium (0.5 mg/kg), insuﬃcient to induce
anxiolytic eﬀects. After 30 min, the mice were subjected to the PMT to
determine the possible synergic eﬀect.
Experiment III: Sub-threshold doses of alprazolam (ALP,
0.03 mg/kg), an anxiolytic, triazolobenzodiazepine (thiazolo-BDZ),
and T. parthenium (0.5 mg/kg) were administered together to mice
that, after 30 min, were subjected to the PMT.
To determine whether antidepressant drugs are able to block or
enhance the antidepressant-like eﬀects of T. parthenium in the forced
swimming paradigm, experiments to antagonize and synergize the
drug were designed.
Experiment I: A group was treated with T. parthenium at a single
sub-eﬀective dose (5 mg/kg) in combination with a sub-threshold dose
of Fluoxetine (FLX; 10 mg/kg), a serotonin reuptake inhibitor. Thirty
min later the mice were tested in the FST.
Experiment II: Two independent groups of eight animals each
were pretreated with PCPA (100 mg/kg, an inhibitor of serotonin
synthesis), and a third group was given only the vehicle, once a day,
for 4 consecutive days (Cassani et al., 2014). After the last adminis-
tration of PCPA, one group was treated with T. parthenium (20 mg/kg,
p.o.) and the remaining groups only received vehicle. Then, all mice
were tested in the FST 30 min later.
2.2.2.5. Statistical analysis. Results are present as the mean ±
Standard Error of the Mean (SEM). Data were analyzed with
Kruskal–Wallis ANalysis Of VAriance (ANOVA) on ranks (*p < 0.05,
**p < 0.01, and ***p < 0.001), followed by the Mann–Whitney rank
sum test. The SigmaPlot ver. 12.5 statistical software program was used
to make the graphics and to conduct the analysis.
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3. Results
3.1. Chemical Analysis of aqueous extract of T. parthenium
Santin and santamarine were isolated from the organic extracts and
utilized as standards in the HPLC-MS analysis. Sesquiterpene lactones,
such as parthenolide or canin, were not isolated from the organic
extract and were not identiﬁed in the aqueous extract of T. parthenium.
The aqueous extract of T. parthenium was found to contain the ﬂavone
santin [1] at 7.4% (relative abundance), and santamarine [2] (an
isomeric form of parthenolid), a sesquiterpene lactone, was found at
4% (Fig. 1). It has been described that parthenolid is present only in
trace in Mexican samples of feverfew (Hausen, 1981).
The BBT was employed to measure the anxiolytic eﬀects of diﬀerent
doses of T. parthenium aqueous extract. As presented in Table 1, T.
parthenium at 5, 10, and 20 mg/kg decreased the cumulative time that
animals spent burying the prod and increased burying behavior latency
in a dose-dependent fashion; this eﬀect was similar to the results
produced by DZ at 0.5 mg/kg. The one-way ANOVA on ranks revealed
that for the two parameters analyzed (cumulative burying behavior and
burying behavior latency), both T. parthenium and DZ exhibited
statistically signiﬁcant diﬀerences with respect to the control group
(H=29.420; df=5; p≤0.001).
3.2. Eﬀects of increasing doses of T. parthenium on the PMT are
depicted in Fig. 2
The acute treatment with T. parthenium at 0.5, 1, 5, and 10 mg/kg
produced a signiﬁcant increase in both % of time spent in the open
arms (H=30.22; df=6; p≤0.001), and percentage of open-arm entries
(H=32.75; df=6; p≤00.1) compared with the vehicle-treated group.
Similarly, mice treated with DZ at doses ranging from 0.25 to 2.0 mg/
kg produced a signiﬁcant increase in % of time spent in the open arms
in a dose-dependent manner (H=32.292; df=4; p≤0.001) and percen-
tage of open-arm entries (H=28.530; df=4; p≤0.001), and mice treated
with ALP at 0.25 and 0.5 mg/kg also spent signiﬁcantly more time on
the open arms and presented an increased percentage of entries on the
open arms. At higher doses (20 and 40 mg/kg), T. parthenium did not
produce changes compared with the vehicle-treated group.
Other parameters measured in the PMT are illustrated in Table 2.
Animals treated with T. parthenium (1, 5, 10, 20, and 40 mg/kg) also
demonstrated increases in time spent in head dipping (H=20.410;
df=6; p≤0.01), while time spent on the CP only increased signiﬁcantly
with T. parthenium at 40 mg/kg (H=13.6; df=6; p≤0.03). Likewise,
total arm entries diﬀered only at major T. parthenium doses (20 and
40 mg/kg) from those of the vehicle-treated group.
In the FST, as presented in Fig. 3, T. parthenium at 10-, 20-, and
40-mg/kg doses signiﬁcantly reduced immobility time with respect to
the control group (H=33.590; df=5; p≤0.001). In a similar manner,
ALP at 0.03 and 0.062 mg/kg signiﬁcantly reduced immobility time
compared with the control group (H=22.10; df=2; p≤0.001). In
contrast with T. parthenium and ALP, acute FLX administration was
not able to modify the immobility behavior, this fact in concordance
with those previously reported (Martínez-Vázquez et al., 2012).
All of the drugs were tested in the OFT, and the eﬀects of T.
parthenium on the locomotor and exploratory activity of the experi-
mental animals are exhibited in Table 3. T. parthenium did not modify
the count number (H=19.18; df=6; p=0.51) or alter the rearing number
(H=12, df=6, p=0.06) compared with the control group, T. parthenium
did not alter any exploratory parameters in the OFT. In addition, no
drug modiﬁed the ambulatory behavior of the animals tested (data not
shown).
3.3. Eﬀects of co-administration of T. parthenium plus PTX and plus
ALP in the PMT
To determine whether the GABAergic antagonist Picrotoxin could
block the anxiolytic actions of T. parthenium, an anxiolytic dose of T.
parthenium (5 mg/kg) was jointly administered with PTX at 0.5 mg/
kg; after 30 min, the experimental animals were subjected to the PMT.
As can be observed in Table 4, treatment with PTX alone at 0.5 mg/kg
did not produce any eﬀect in comparison with the control group, while
this same PTX dose was able to block the anxiolytic eﬀect produced by
T. parthenium when the two were jointly administered. In addition, the
T. parthenium /PTX combination reduced the % of time spent in open
arms by 70% with respect to the control group.
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Fig. 1. HPLC and structural characteristics of santin [1] and santamarine [2], secondary metabolites present in the aqueous extract of Tanacetum parthenium. RT=33.6 min, C18H16O7
RT=30.3 min, C15H20O3 Exact mass 344.3154 Exact mass 248.1412.
Table 1
Effect of TP and DZ (0.5 mg/kg) on the burying latency time and burying cumulative
time in the Burying Behavior Test.
Treatment (mg/kg) Burying latency time (s) Burying cumulative time (s)
Control 32.90 ± 5.99 76.44 ± 10.92
DZ 0.5 35.97 ± 4.12 36.79 ± 5.68***
TP 1 28.90 ± 6.36 70.62 ± 11.05
TP 5 26.43 ± 12.56 31.12 ± 4.32**
TP 10 38.43 ± 11.45 9.28 ± 4.32***
TP 20 34.44 ± 7.06 6.71 ± 2.51***
H=10.1, df=5, p=0.072 H=29.4, df=5, p≤0.001
Effect of treatment with single dose (p.o.) of TP at 1, 5, 10, 10, and 20 mg/kg and single
treatment with diazepam (DZ 0.5 mg/kg), by intraperitoneally via in the BBT in mice. All
results are expressed as the mean ± SEM of 8 animals. Comparisons were made using the
Kruskal-Wallis analysis of variance based on rank, followed by the Mann-Whitney-U-
test.
*** p < 0.001.
** p < 0.01.
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Table 2
Effects of a single-dose treatment with the TP, DZ, and ALP upon the behavioral parameters recorded in the elevated plus-maze test in mice.
Treatment (mg/kg) TCA %TCA Total arm entries central platform time (s) time spent in head dipping (s)
VEHICLE 176.4 ± 11.5 75.5 17.37 ± 1.1 66.2 ± 10.9 13 ± 0.8
TP0.5 138.9 ± 10.5** 70 19.25 ± 1.5 61.5 ± 10.8 14.1 ± 1.1
TP1 106 ± 11.6** 49 18.6 ± 1.6 83.5 ± 11.2 27.7 ± 3.5***
TP 5 127 ± 6*** 40 20.8 ± 1.3 79.28 ± 8.9 23.3 ± 2.2***
TP10 162.2 ± 11.2 69 19.3 ± 0.7 63.2 ± 6.9 17 ± 3.3**
TP20 143.4 ± 7.7 71 24.2 ± 1.2*** 99.1 ± 10.8 18 ± 2.3**
TP40 152.9 ± 8.7 76 22.2 ± 1.65** 98.8 ± 5.6* 16 ± 2.3**
H=18.36, df=6. P=0.005 H=17.78, df=6, p=0.007 H=13.60, df=6, p≤0.03 H=20.41, df=6, p=0.002
VEHICLE 216.4 ± 10.9 79 16.3 ± 1.2 66.3 ± 6.9 10.25 ± 1
DZ 0.25 143 ± 8*** 45 15.1 ± 1.3 117.6 ± 6.2*** 11.87 ± 1
DZ 0.5 129.3 ± 5*** 63 19.3 ± 0.8 93.9 ± 6.5* 14.3 ± 1
DZ 1 110 ± 5.7** 58 19 ± 2.1 77.31 ± 16 17.5 ± 1.8
DZ 2 89.3 ± 7.1*** 39 19.2 ± 2 72.2 ± 11.7 22 ± 2.1
30.06, df=4, p≤0.001 H=6.41, df=4, p≤0.17 H=21.8, df=4, p≤0.001 H=18.35, df= 4, p≤0.001
VEHICLE 178 ± 10.4 76 16.7 ± 1 65.4 ± 9.6 13. ± 0.7
ALP 0.06 173.3 ± 5.1 79 14.5 ± 1.3 80.9 ± 7.4 10.2 ± 1.4
ALP 0.12 188.2 ± 11.9 80 14.1 ± 2.1 63.9 ± 7.5 12.6 ± 1.7
ALP 0.25 66.7 ± 8.9*** 56 21 ± 1.9 98.9 ± 10.7 25.2 ± 1.8
ALP 0.5 116.1 ± 7.11*** 67 31.6 ± 2.3*** 54.3 ± 9. 29.8 ± 2.5
H=32.32, df=4, p≤0.001 H=24.1, df=4, p≤0.001 H=6.4, df=4, p≤0.17 H=28.34, df=4, p=≤0.001
Effects of a single-dose treatment with the TP (5–40 mg/kg), DZ (0.25–2 mg/kg), and ALP (0.06–0.5 mg/kg) upon time spent in close arms (TCA), % TCA, total arm entries, central time
(s), and time spent in head dipping (s) the in the elevated plus-maze test in mice. All results are expressed as the mean ± s.e.m. of 8 animals. Comparisons were made using the Kruskal-
Wallis analysis of variance based on rank, followed by the Mann-Whitney-U-test.
** p < 0.01.
*** p < 0.001.
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Fig. 2. Eﬀects of a single-dose oral with the TP and eﬀect of a single-dose intraperitoneally of DZ and ALP on the elevated plus-maze test in mice. Eﬀects of TP via orally dose, and DZ
and ALP intraperitoneally dose on the elevated plus-maze test in mice. Percentage of entries and time spent in open arms (open arms/total×100) is shown. TP (aqueous extract of
Tanacetum parthenium) was administered per os. DZ (diazepam) and ALP (alprazolam) were administered intraperitoneally. Data are expressed as the mean ± SEM. of groups of 8–9
animals. Comparisons were made using the Kruskal-Wallis analysis of variance based on rank, followed by the Mann-Whitney-U-test. Signiﬁcantly diﬀerent from vehicle treated group
*p≤0.05, **p≤.01, and ***p≤0.001.
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In this same paradigm, the combination of a sub-threshold dose of
T. parthenium (0.5 mg/kg) and an ineﬀective dose of ALP (0.12 mg/
kg) were evaluated. Our results revealed that the combination of T.
parthenium /ALP at a non-eﬀective dose, signiﬁcantly increased time
and percentage spent in open arms and reduced time spent in closed
arms in the PMT, compared with the control group (Table 4).
3.4. Eﬀects of co-administration of T. parthenium plus ALP, plus FLX,
and plus PCPA in the FST
To determine whether ALP could enhance the antidepressant-like
actions of T. parthenium, a combination of non-eﬀective doses of T.
parthenium (5 mg/kg) and ALP (0.03 mg/kg) were co-administered
and the eﬀect was evaluated in the FST. As demonstrated in Fig. 3,
ALP, a benzodiazepine-type antidepressant drug at 0.03 mg/kg, in
combination with 5 mg/kg of T. parthenium, providing an antidepres-
sant-like eﬀect with a statistically signiﬁcant diﬀerence in the Mann–
Whitney test: T=97; n=8, and p≤0.001. Likewise, the combination of
threshold doses of T. parthenium with a single, non-eﬀective dose of
FLX (10 mg/kg) facilitated the antidepressant actions of T. parthenium
(T=89; n=8; p=0.001) compared with the control-treated group.
We explored the involvement of the 5-HT system in the antide-
pressant-like eﬀect of T. parthenium. For this purpose, 5-HT was
depleted by means of the tryptophan hydroxylase inhibitor p-chlor-
ophenylalanine (PCPA, 100 mg/kg, i.p., 4 days) prior to treatment with
the T. parthenium eﬀective dose (20 mg/kg). The consequent results
showed that PCPA blocked the anti-immobility eﬀect of T. parthenium,
because the group treated with T. parthenium plus PCPA did not
exhibit a signiﬁcant diﬀerence with respect to the control group
(Mann–Whitney test: T=51; n=8; p=0.08).
4. Discussion
Anxiety and depression disorders are highly prevalent conditions
and entertain high levels of comorbidity (Kessler et al., 2010; Kelsey
and Collimore, 2014). Individuals aﬀected by both anxiety and
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Fig. 3. Eﬀects of TP, ALP, and FLX on immobility time in the Forced Swimming Test. Antidepressant-like eﬀects of an aqueous extract of T. parthenium (TP), alprazolam (ALP), and
ﬂuoxetine (FLX) on the forced swimming test. Data are expressed as the mean ± SEM of groups of eight animals; Comparisons were made using the Kruskal-Wallis analysis of variance
based on rank, followed by the Mann-Whitney-U-test. Signiﬁcantly diﬀerent from vehicle treated group (VEH) *p≤0.05 and ***p≤0.001.
Table 3
Effect of aqueous extract of leaves of Tanacetum parthenium (TP) on the ambulatory
activity of mice in the OFT.
Treatment (mg/kg) n Count number/5 min
mean ± s.e.m.
control 7 42.85 ± 4.96
TP 0.5 8 33.00 ± 2.98
TP 1 8 55.62 ± 4.53
TP 5 8 47.71 ± 3.57
TP 10 8 37.12 ± 3.29
TP 20 8 36.62 ± 1.99
TP 40 8 39.00 ± 1.75
H=2.87, df=6, p=0.579
control 8 50.75 ± 2.78
DZ 0.25 8 58.12 ± 5.85
DZ 0.5 8 59.50 ± 5.64
DZ 1.0 8 46.87 ± 5.91
DZ 2.0 8 44.25 ± 6.16*
H=19.18, df=4, p=0.04
Results are expressed as mean ± SEM statistical comparisons were made between the
saline-treated group and the experimental groups using a Kruskal-Wallis One Way
Analysis of Variance on Ranks, followed by the Mann-Whitney Rank Sum Test (p* <
0.05).
Table 4
Effects of the combination of TP (0.5 mg/kg) plus PTX (0.5 mg/kg), TP (0.5 mg/kg) plus
ALP (0.12 mg/kg), and TP (0.5 mg/kg) plus MUS (0.5 mg/kg) in plus-maze test.
Treatment
(mg/kg)
Time spent in open
arms (s)
Time spent in close
arms (s)
% Time spent in
open arms (s)
control 57.2 ± 4.3 176.4 ± 11.5 21.2 ± 2.0
TP 0.5 59.5 ± 3.9 138.9 ± 10.5 30.4 ± 2.2
PTX 0.5 47.3 ± 2.6 211.1 ± 7.3++ 18.4 ± 1.3
ALP 0.12 43.3 ± 6.0 194.1 ± 11.7 18.5 ± 2.8
TP 5/PTX 0.5 13.0 ± 2.0++ 231.9 ± 8.1+++ 5.3 ± 0.7+++
TP 0.5/ALP
0.12
90.7 ± 9.28 102.3 ± 7.8*** 46.7 ± 2.9***
MUS 0.5 66.1 ± 4.30 144.0 ± 9.1 31.5 ± 3.6
MUS 0.5/TP
0.5
124.8 ± 12.9*** 107.0 ± 17.9*** 54.8 ± 5.6***
H=61.51, df=9,
p≤0.001
H=49.02, df=9,
p≤0.001
H=59.11, df=9,
p≤0.001
Effect of co-administration of TP at 0.5 mg/kg (p.o.) with picrotoxin (PTX; 5 mg/kg, IP),
TP (0.5 mg/kg) with alprazolam (ALP; 0.12 mg/kg, IP), and TP (0.5 mg/kg, p.o.) with
muscimol (MUS, 0.5 mg/kg, IP). All results are expressed as the mean ± SEM of 8
animals. Comparisons were made using the Kruskal-Wallis analysis of variance based on
rank, followed by the Mann-Whitney-U-test: ** p < 0.01 (*signiﬁcant increase with
respect to control group), (+ signiﬁcant decrease with respect to control group).
++ p < 0.01.
+++ p < 0.001.
*** p < 0.001.
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depressive disorders concurrently have generally exhibited greater
levels of functional impairment, reduced quality of life, and poorer
treatment outcomes compared with individuals with only one of these
disorders (Lamers et al., 2011).
As mentioned previously, Tanacetum parhtenium is employed by
several medical conditions, although to date, few in vivo experiments
have been carried out. In the present work and, to our knowledge for
the ﬁrst time, we studied the eﬀects of the aqueous extract of T.
parhtenium on the Central Nervous System (CNS).
One of main purposes of the present study was to analyze the
anxiolytic-like eﬀects of the aqueous extract of T. parthenium. To allow
for this, the eﬀects of T. parthenium were evaluated in two predictive
animal models of anxiety. In the ﬁrst assay, experimental anxiety
values were determined employing the defensive burying behavior test;
this is a conﬂict model largely validated for the study of both anxiolytic
and anxiogenic drugs (Treit, 1985; López-Rubalcava et al., 2006). Our
results revealed that the aqueous extract of T. parthenium at 5, 10, and
20 mg/kg produced a signiﬁcant dose-dependent reduction compared
with the control group in burying accumulative time, similar to the
eﬀects of Diazepam (DZ). It has been reported that compounds with
anxiolytic actions decrease burying behavior, conjointly with burying-
time latency. Some authors have considered that this behavior is the
animals' reactivity in an inverse manner and indicate that classic
anxiolytics such as Benzodiazepines (BDZ) decrease reactivity, (López-
Rubalcava et al., 2000). It is noteworthy that, herein, the decrease in
burying behavior was not accompanied by an increase in burying
behavior latency; thus, unlike DZ, T. parthenium clearly produced an
anxiolytic-like eﬀect without aﬀecting animal reactivity. The anxiolytic
eﬀect of T. parthenium was also evaluated in the elevated Plus-Maze
Test (PMT) (Lister, 1987; López-Rubalcava et al., 2006). The anxioly-
tic-like eﬀect of TP was indicated by a signiﬁcant increase in both entry
number and time spent in open arms. These responses were observed
at lower doses of 0.5–10 mg/kg, achieving best eﬀect at 5- and 10-mg/
kg doses. Frequency of entries is the natural spatiotemporal index of
anxiety; it is reduced by anxiolytic drugs such as DZ and can be
increased by anxiogenic drugs such as picrotoxin (PTX) (López-
Rubalcava et al., 2000). In agreement with these ﬁndings, we found
that T. parthenium demonstrated an anxiolytic proﬁle similar to that of
this antianxiety drug. Reduction of time spent on the Central Platform
(CP) comprises another index of a reduced “decision-making” (hesitant
behavior) behavior. Both parameters are accepted as reliable indicators
of anxiety and fearfulness (Rocha et al., 2002). T. parthenium at any
dose did not alter time spent on CP or in total arm entries. These
observations also indicate that the anxiolytic-like eﬀect of T. parthe-
nium is selective and is not associated with a general stimulation of
locomotor activity as a consequence of exposure to a novel environ-
ment. These facts were also conﬁrmed by Open Field Test (OFT)
results, which did not show any change in the locomotor activity of
mice treated with T. parthenium. The anxiolytic eﬀects induced by in
the PMT were similar to those produced by DZ, an anxiolytic and
sedative BDZ that acts as a positive allosteric modulator of the GABA at
the BDZ site. Additionally, T. parthenium actions were also compared
with those induced with alprazolam (ALP), a full agonist to the GABAA
receptor (Rang et al., 1996; Hascoet and Bourin, 1997) that, in
addition to its anxiolytic eﬀects produces antidepressant eﬀects.
Thus, the three drugs demonstrated a similar anxiolytic eﬀect, with
ALP that of greatest pharmacological potency.
To explore the possible involvement of the GABAergic neurotrans-
mitter system in the anxiolytic actions of T. parthenium, we conducted
independent synergic experiments in which non-eﬀective doses of T.
parthenium (0.5 mg/kg) and sub-threshold doses of MUS (0.5 mg/kg)
or ALP (0.12 mg/kg) were jointly administered. Our results revealed
that the anxiolytic-like eﬀect of T. parthenium in the PMT was
enhanced with both concomitant administration of T. parthenium
with MUS as well as with ALP. Furthermore, PTX is a non-competitive
antagonist of the GABAA receptor that speciﬁcally acts at a site
associated with the chloride channel preventing the inhibitory action
of GABA, which increase anxiety levels (Petty et al., 1995). In this
study, this drug was able to completely block the actions of T.
parthenium in the PMT. It could be concluded that T. parthenium
interacts with this neurotransmitter system to mediate its anxiolytic-
like actions or T. parthenium contains compounds that facilitate
GABAergic transmission. In this regard, the anxiolytic actions of
numerous ﬂavonoid compounds have been described (Estrada-Reyes
et al., 2012; 2014); thus, it is likely that santin [1] could be
contributing to the actions of T. parthenium. In addition, these results
are consistent with those previously reported in an in vitro assay (Jäger
et al., 2009). Taken together, these results suggest that T. parthenium
interacts with the GABAA receptor, probably at GABAA receptor
subtypes, in binding sites diﬀerent from those at classical BDZ eﬀects,
produce anxiolytic eﬀects. However, it is necessary to conduct speciﬁc
studies to determine the speciﬁc target.
On the basis of T. parthenium in traditional medicine, another
purpose was evaluated in this study of its antidepressant-like action in
the Forced Swimming Test (FST) in mice. The FST induces a state of
immobility in animals facing an inescapable situation of swimming;
such immobility behavior has been hypothesized to reﬂect hopeless-
ness, which may in turn reﬂect an aspect observed in depressive
disorders in humans. Thus, the antidepressant-like activity of a drug is
expressed by a decrease in the immobility of animals subjected to the
FST. Our results demonstrated that T. parthenium induced a dose-
dependent reduction of immobility time in the FST at 10, 20, and
40 mg/kg: this antidepressant eﬀect was similar to that produced by
ALP (Rang et al., 1996; Hascoet and Bourin, 1997; Hascoet and
Bourin, 1997).
Monoaminergic, serotoninergic, and noradrenergic systems are
known to play major roles in major depression (Perona et al., 2008).
However, the GABA system also participates in the antidepressant
actions of thiazole-BDZ such as ALP that, in addition to enhancing the
release of serotonin (5-HT) in the hippocampus to produce antide-
pressant actions, may act by means of a GABAergic mechanism that is
independent of the BDZ-site receptor (Jonas and Cohon, 1993; Kalueﬀ
and Nutt, 2007; Al-Tubuly et al., 2008). Thus, as may be observed in
Fig. 3, ﬂuoxetine (FLX) was not able to reduce immobility time in the
FST, as might be expected. This fact agrees with previous reports on
Selective Serotonin Reuptake Inhibitor (SSRI) antidepressant drugs,
such as FLX at an acute dose, which does not exert an antidepressant-
like eﬀect on the FST (Cassani et al., 2014, 2015).
Interestingly, the combination of a sub-eﬀective dose of FLX
(10 mg/kg) in combination with a non-eﬀective dose of T. parthenium
(5 mg/kg) revealed to evident antidepressant activity in the FST.
The synergistic antidepressant-like eﬀect produced by a sub-
eﬀective dose of T. parthenium and FLX comprised an interesting
result that may derive from the eﬀect of T. parthenium in the FST and
an interaction with the serotoninergic system. In accordance with our
earlier ﬁndings, we depleted 5-HT by means of the tryptophan
hydroxylase inhibitor p-chlorophenylalanine (PCPA) before treatment
with TP. PCPA blocked the antidepressant actions of T. parthenium in
the FST. These ﬁndings support the involvement of the serotoninergic
neurotransmitter system in the antidepressant action of T. parthe-
nium. In general, a large number of evidences indicate that the
serotonin neurotransmitter system is strongly involved in the regula-
tion of mood and anxiety disorders (Millan, 2003). Several pieces of
evidence have been implicated in abnormalities in serotonergic trans-
mission in the pathology of depressive disorders. However, we think
that it is necessary to perform experiments aimed at determining the
speciﬁc mechanism underlying the anxiolytic and antidepressant
actions of T. parthenium.
Previous studies have shown that many psychostimulant drugs can
decrease immobility behavior in the FST. These drugs also cause
marked increases in the ambulatory activity of the experimental
animals. Therefore, to avoid a false positive antidepressant eﬀect, the
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locomotor activity of animals subjected to the FST was evaluated
employing the OFT. Our results showed that T. parthenium signiﬁ-
cantly reduced immobility time in the FST without increasing ambu-
latory activity, which conﬁrmed that T. parthenium induces a clear,
antidepressant-like eﬀect in the FST.
In summary, numerous neurotransmitter systems underlie the
states of anxiety and depression. It is accepted that BDZ-type anxio-
lytics act enhancing the eﬀect of GABA at the GABAA receptor.
Although these classical BDZ are eﬀective anxiolytics, they lack the
antidepressant eﬀects. In this study, we demonstrated that T. parthe-
nium induced both anxiolytic and antidepressant actions that are
mediated, at least in part, by its interaction with GABAA receptors.
Additionally, our ﬁndings also show the involvement of the serotoner-
gic neurotransmitter system in the antidepressant actions of T.
parthenium.
5. Conclusions
This study showed that a single oral treatment of T. parthenium
induces anxiolytic- and antidepressant-like eﬀects in several behavioral
paradigms in mice. T. parthenium did not induce alterations in
locomotor activity. These results led to evidence of the participation
of the GABAergic and serotonergic systems in the actions of T.
parthenium. Our results support the use of Tanacetum parthenium
in traditional medicine and reveal its utility for the treatment of
comorbid disorders of depression and anxiety.
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